Cover Image
市場調查報告書

市場進入的課題:氣喘、COPD (歐盟5國)

Market Access Impact (EU5) [Asthma/COPD]

出版商 FirstWord 商品編碼 531819
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:氣喘、COPD (歐盟5國) Market Access Impact (EU5) [Asthma/COPD]
出版日期: 2017年07月01日 內容資訊: 英文
簡介

本報告依據歐盟5國 (法國、義大利、德國、西班牙、英國)的150名呼吸系統科醫生的氣喘、COPD治療藥的處方趨勢調查,提供市場進入的各種障礙與對處方的影響,主要11個品牌藥的處方相關比較分析、個別分析。

調查對象

  • Anoro (umeclidinium/vilanterol; GSK)
  • Daxas (roflumilast; AstraZeneca)
  • Eklira (aclidinium; AstraZeneca)
  • Onbrez (indacaterol; Novartis)
  • Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
  • Seebri (glycopyrronium; Novartis)
  • Seretide (fluticasone/salmeterol; GSK)
  • Spiriva (tiotropium; Boehringer Ingelheim)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Ultibro (indacaterol/glycopyrronium; Novartis)
  • Xolair (omalizumab; Novartis)

調查課題

  • 各種障礙對市場進入的影響
    • 醫生最大量開立處方的品牌為何?
    • 受市場障礙影響的處方數是多少?
    • 有最大影響的障礙為何?
  • 各品牌的障礙的影響
    • 開立各品牌處方的醫生數是多少?未開立處方但考慮的數量是多少?
    • 不開立處方的理由為何?其替代處方為何?
    • 爭奪市場佔有率的競爭品牌為何?
目錄
Product Code: 596200753

Market barriers cost most brands share, but awareness is a bigger issue for some

In the EU5 countries, market barriers affect a modest 15% of asthma/COPD prescriptions, but they're siphoning market share from most of the brands we surveyed. That lost share goes to a handful of brands, putting the market leaders even further ahead. Meanwhile some brands have a bigger problem: doctors aren't prescribing them because they don't know they exist.

Market Access Impact: Asthma/COPD (EU5) shows you how widely prescribed your brand is, and reveals how 7 barriers affect your market share. You'll learn how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 150 pulmonologists, the report covers 11 major therapies from AstraZeneca, Boehringer Ingelheim, GSK, and Novartis.

Top Takeaways

  • Barriers affect nearly 15% of prescriptions: Most barriers have a more or less equal overall impact, but each one affects some brands more than others.
  • Most brands lose share: 7 of the 11 surveyed brands lose market share because of barriers, although those losses tend to be modest.
  • 2 brands have a big lead: They're prescribed by at least 10% more doctors than their closest competitor, and enjoy a sizeable market share advantage.
  • 2 barriers are holding one brand back: 30-40% of surveyed doctors can't prescribe it due to high cost or patient type recommendations.
  • Not all doctors see the problem: At least half of the surveyed doctors don't experience any barriers with most of the surveyed brands.
  • Need for improvement: Up to almost 40% of doctors either wouldn't prescribe many of the surveyed brands, or haven't heard of them at all.

Insight into 11 Asthma/COPD Disease Drug

  • Anoro (umeclidinium/vilanterol; GSK)
  • Daxas (roflumilast; AstraZeneca)
  • Eklira (aclidinium; AstraZeneca)
  • Onbrez (indacaterol; Novartis)
  • Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
  • Seebri (glycopyrronium; Novartis)
  • Seretide (fluticasone/salmeterol; GSK)
  • Spiriva (tiotropium; Boehringer Ingelheim)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Ultibro (indacaterol/glycopyrronium; Novartis)
  • Xolair (omalizumab; Novartis)

Exploring Important Market Access Issues

Market Access Impact: Asthma/COPD (EU5) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 pulmonologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with Parkinson's disease in the last month

We conducted the survey between June 1st and 5th, 2017.

Back to Top